Abstract |
Imiquimod is a topically active imidazoquinoline immunomodulator agent. It works as an indirect antiviral and antitumoral and stimulates the production of INF-alpha and various other cytokines. We assayed topical imiquimod in treating early stages of mycosis fungoides. We applied imiquimod 5% cream in four patients with multi-treatment resistant plaques of MF (stages IA and IIB). We applied it on one patient in association with systemic INFalpha-2a. We observed a complete clinical clearance of the lesions in all four patients. In three cases we achieved a complete histopathological clearance and in one case a partial histopathological clearance. The patient treated with imiquimod and systemic INFalpha-2a showed the most spectacular improvement with a rapid total response. We ascribe this improvement to a synergic effect of imiquimod and systemic INFalpha-2a treatment. Before the introduction of imiquimod, this patient had been treated for 2 years with systemic INFalpha-2a alone, without any evidence of clinical response. Imiquimod could be an effective therapy for early-stage disease of CTCL, used alone or in combination with systemic immunomodulatory therapy.
|
Authors | M Covadonga Martínez-González, M Magdalena Verea-Hernando, M Teresa Yebra-Pimentel, Jesús Del Pozo, Marta Mazaira, Eduardo Fonseca |
Journal | European journal of dermatology : EJD
(Eur J Dermatol)
2008 Mar-Apr
Vol. 18
Issue 2
Pg. 148-52
ISSN: 1167-1122 [Print] France |
PMID | 18424373
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Aminoquinolines
- Immunologic Factors
- Imiquimod
|
Topics |
- Administration, Cutaneous
- Aged
- Aminoquinolines
(administration & dosage, therapeutic use)
- Female
- Humans
- Imiquimod
- Immunologic Factors
(administration & dosage, therapeutic use)
- Male
- Middle Aged
- Mycosis Fungoides
(drug therapy, pathology)
- Treatment Outcome
|